Russia and China will develop new drugs against treatment-resistant bacteria

The Russian Sirius University, in partnership with China’s Jilin University, is set to explore innovative approaches for the treatment of infectious diseases, particularly those that resist current available medications. According to Roman Ivanov, the Director of the Sirius Research Center for Translational Medicine, a new class of drugs may emerge as a consequence.
According to him, the Chinese university has a strong foundation in the field of drug delivery using ferritin nanoparticles. This enables the study of the antimicrobial activity of developments both in vitro and in vivo. This technology serves as a potential foundation for the creation of new drugs, which could lead to the emergence of a completely novel class of medications. This breakthrough is particularly significant for the treatment of infections caused by antibiotic-resistant strains of Pseudomonas aeruginosa.
“The possibility of using a drug based on nanoparticles from the protein ferritin is being studied. The aerobic Gram-negative bacterium Pseudomonas aeruginosa (Pseudomonas aeruginosa) causes life-threatening acute and chronic infections in humans. Of particular relevance is the search for new approaches to the treatment of infectious complications of cystic fibrosis, a severe hereditary disease, caused by this pathogen,” Ivanov said.